This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
by Zacks Equity Research
Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.
Moderna Gets Rating Downgrade, Takes Safety Pledge, Stock Down
by Zacks Equity Research
Moderna (MRNA) pledges with eight other pharma companies to ensure commercialization of a safe and effective vaccine. However, anticipated competitive pressure weighs on the stock.
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Coronavirus Vaccine Makers May Make Joint Safety Pledge
by Kinjel Shah
The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.
Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress
by Kinjel Shah
AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PFE, XOM, CRM, AMGN and AAPL
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Stock Market News for Sep1, 2020
by Zacks Equity Research
U.S. stock markets closed mostly lower on Monday as investors booked profit after a week-long rally.
Lessons for Equity Investors From Dow Jones' Big Shake-Up
by Nilanjan Choudhury
The Dow Jones is a rare example of an index constructed on the basis of a component's share price.
AstraZeneca Begins Coronavirus Vaccine US Phase III Study
by Zacks Equity Research
AstraZeneca's(AZN) phase III study to enroll 30,000 adult participants and assess the safety, efficacy and immunogenicity of its COVID-19 vaccine candidate, AZD1222.
Bull of the Day: Salesforce.com (CRM)
by David Borun
This brand-new Dow component continues to beat the estimates and raise guidance.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Dow Turns Green YTD in Old Format: What Will the Revamp Unfold?
by Nalak Das
The revamp is likely to make the Dow more market-friendly and reflect investors' sentiments more accurately.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
VBI Vaccines Up on Coronavirus Vaccine Candidates Selection
by Zacks Equity Research
VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.
Glaxo Receives EU Approval for Multiple Myeloma Drug Blenrep
by Zacks Equity Research
The European Commission lends a nod to Glaxo's (GSK) Blenrep as a monotherapy for patients with relapsed/refractory multiple myeloma, having received at least four previous therapies.
Pfizer (PFE) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dow Jones ETF in Focus on Index Shake-Up
by Sweta Killa
Given the tech sector dominance, many Wall Street analysts believe the post-reshuffle Dow Jones could struggle to catch up with the S&P 500 and the Nasdaq Composite, which have been hitting new highs.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
by Zacks Equity Research
Novartis' (NVS) chronic myeloid leukemia candidate meets primary endpoint in a phase III study.